

COVID-19 CADTH Health Technology Review

Ongoing Trials for Drugs in the Prevention and Treatment of COVID-19

This report is current as of April 16, 2021.

To produce this report, CADTH used a modified approach to the selection of the evidence to meet decision-making needs during the COVID-19 pandemic. Care has been taken to ensure the information is accurate and complete, but it should be noted that international scientific evidence about COVID-19 is changing and growing rapidly.

Version: 22.0
Publication Date: April 2021
Report Length: 44 Pages

Authors: Sirjana Pant, Christine Perras

Cite As: *Ongoing Trials for Drugs in the Prevention and Treatment of COVID-19*. Ottawa: CADTH; 2021 April. (CADTH Health Technology Review).

ISSN: 1922-8147 (online)

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca.

Version	Date of publication	Summary of revisions
1.0	June 9, 2020	Information current as of May 28, 2020
2.0	July 2, 2020	Addition of phase IV trials. Addition of new trials. Information current as of June 19, 2020
3.0	July 8, 2020	Addition of Health Canada's Clinical Trial Database's identifier Addition of new trials. Information current as of July 3, 2020
4.0	July 21, 2020	Addition of new trials. Information current as of July 17, 2020
5.0	August 6, 2020	Addition of new trials (to February 28, 2021). Information current as of July 31, 2020. Removal of all trials of chloroquine/hydroxychloroquine.
6.0	August 18, 2020	Addition of new trials. Information current as of August 14, 2020.
7.0	September 1, 2020	Addition of new trials. Information current as of August 28, 2020.
8.0	September 16, 2020	Addition of new trials (to March 31, 2021). Information current as of September 11, 2020.
9.0	September 29, 2020	Addition of new trials. Information current as of September 25, 2020.
10.0	October 16, 2020	Addition of new trials (to April 30, 2021). Information current as of October 9, 2020.
11.0	October 28, 2020	Addition of new trials (to May 31, 2021). Information current as of October 23, 2020.
12.0	November 13, 2020	Addition of new trials (to June 30, 2021). Information current as of November 6, 2020.
13.0	November 26, 2020	Addition of new trials (to July 31, 2021). Information current as of November 20, 2020.
14.0	December 8, 2020	Addition of new trials (to August 31, 2021). Information current as of December 4, 2020.
15.0	December 23, 2020	Addition of new trials (to September 30, 2021). Information current as of December 18, 2020.
16.0	January 13, 2021	Addition of new trials (to October 31, 2021). Information current as of January 8, 2021.
17.0	January 26, 2021	Addition of new trials (to November 30, 2021). Information current as of January 22, 2021.
18.0	February 11, 2021	Addition of new trials (to December 31, 2021). Information current as of February 5, 2021.
19.0	February 25, 2021	Addition of new trials (to January 31, 2022). Information current as of February 19, 2021.
20.0	March 11, 2021	Addition of new trials (to February 28, 2022). Information current as of March 5, 2021.
21.0	March 31, 2021	Addition of new trials (to March 31, 2022). Information current as of March 26, 2021.
22.0	April 21, 2021	Addition of new trials (to April 30, 2022). Information current as of April 16, 2021. Final update.

About This Document

This report provides information on the ongoing phase II/III, phase III, and phase IV randomized controlled trials (RCTs) of drugs intended to prevent or treat COVID-19. It is important to note that this report is not a systematic review and does not include a critical appraisal of studies. It is not intended to provide any recommendations.

This is the final update to this report, and the information is current to April 16, 2021. For more recent information, the reader is referred to these resources:

[Drugs and vaccines for COVID-19: Authorized clinical trials – Canada.ca](https://www.canada.ca/en/health-canada/services/drugs-vaccines/clinical-trials/authorized-clinical-trials.html)

[Cochrane COVID-19 Study Register](https://www.cochrane.org/covid-19-study-register)

[Search of: COVID-19 – List Results – ClinicalTrials.gov](https://www.clinicaltrials.gov/ct2/search?rank=1&term=COVID-19)

Objective

To describe the trial characteristics and estimated primary completion dates of the ongoing phase II/III, phase III, and phase IV RCTs evaluating drugs to prevent or treat COVID-19.

Selection Criteria and Methods

The phase II/III, phase III, and phase IV RCTs were identified from the ClinicalTrials.gov website¹ using the inclusion criteria in Table 1.

Table 1: Selection Criteria

Criteria	Description
Population	Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) or at risk (pre-/post-exposure prophylaxis or prevention)
Intervention	Drugs for treatment and prevention
Comparator	No restriction
Outcomes	No restriction
Study designs	Phase III (including phase II/III) and phase IV RCTs that are: recruiting; not yet recruiting; enrolling by invitation; or active, but not recruiting
Estimated primary completion date	By April 30, 2022

Exclusion Criteria

Non-drugs (e.g., devices), natural products, nutraceuticals, plasma products, stem cell therapies, and vaccines were excluded from this report. Trials on plasma products and vaccines are provided in separate reports. Non-randomized studies and single-arm trials were excluded. All trials of chloroquine, hydroxychloroquine, and remdesivir were also excluded from this review, as their trial information is available in published CADTH reports.²

The results were tabulated according to indication (prevention and treatment) and phase of clinical development and are presented in order of estimated primary trial completion dates (with the earliest first). Health Canada's Clinical Trial Database's identifier is also noted in the tables (Health Canada [HC] Control No.).³

The tables will be updated bi-weekly or if key trial data or results become available. When a trial's status changes to "Completed," "Withdrawn," "Terminated," or "Suspended" in ClinicalTrials.gov, the information will be moved to an appendix. A separate report may be initiated to evaluate and critically appraise the evidence once results are published.

Results

As of April 16, 2021, 85 phase II/III, 149 phase III, and 52 phase IV treatment trials; one phase II/III, five phase III and one phase IV pre-exposure trials; and two phase II/II, 13 phase III and one phase IV post-exposure trials met the inclusion criteria (Tables 2 and 3). The sample sizes of the included trials ranged from 20 to 16,500 patients.

Trial populations for most of the trials included hospitalized adult patients; few treatment trials included outpatients (33 trials) or children younger than 16 years (10 trials). Based on dates included in the tables, 143 trials have estimated primary completion dates by the end of April 2021. Twenty-seven trials with Canadian study sites were identified (as highlighted in the tables).

Trials for which the status was changed to "Completed," "Withdrawn," "Terminated," or "Suspended" in ClinicalTrials.gov are depicted in Appendix 1, Table 4.

Limitations

The information provided in this report relies on the information posted on the ClinicalTrials.gov registry. There may be reporting errors in the study records posted on ClinicalTrials.gov. Furthermore, given the rapid changes occurring with the scientific evidence related to COVID-19, the reporting of amendments to the included trial protocols may be delayed. While some trials have reached their primary completion dates, their status are still showing as "recruiting" and results have not yet been posted. Finally, not all ongoing trials are posted to the website and, as such, ClinicalTrials.gov may provide an incomplete picture of the ongoing clinical trials related to COVID-19.

We have chosen to show the earliest trial completion date, that is the "estimated primary trial completion date" (the date on which the data collection was completed for all the primary outcome measures) and not the "estimated trial completion date" (the date on which the last patient was examined or received a treatment) to be able to quickly flag trials that may have results available ahead of the completion of a trial. We have limited our search date from March 1, 2020 to April 30, 2022.

Summary

A total of 309 ongoing phase II/III, phase III, or phase IV drug trials on COVID-19 met the inclusion criteria as of April 16, 2021.¹ Their sample sizes range from 20 to 16,500 patients. Most of the trials are being conducted in hospitalized adult patients, with few trials evaluating children or outpatients. By the end of April 2021, 143 trials will have reached their estimated primary completion dates. Twenty-seven trials have Canadian study sites (as highlighted in the tables).

Table 2: Drugs to Treat COVID-19: Ongoing Randomized Controlled Trials — April 2022 Estimated Primary Completion Date

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Phase IV					
Tocilizumab	NA	MC, OL Israel N = 500	April 29, 2020	Hospitalized adult patients with severe COVID-19 with suspected pulmonary hyperinflammation	NCT04377750
Spirolactone	NA	DB, PC Turkey N = 60	July 21, 2020	Hospitalized adult patients with ARDS due to COVID-19	NCT04345887
Cholecalciferol	COVID-VIT-D	DB Spain N = 80	September 14, 2020	Adult patients with COVID-19	NCT04552951
Bivalirudin	ANTI-CO	DB Qatar N = 100	September 28, 2020	Hospitalized adult patients with COVID-19	NCT04445935
Desferal	NA	OL Egypt N = 200	September 30, 2020	Hospitalized children and adult patients with moderate COVID-19	NCT04389801
Losartan	NA	MC, OL US N = 200	October 6, 2020	Adult patients with mild-to-moderate respiratory symptoms of COVID-19	NCT04340557
Nebulized heparin with or without enoxaparin	NEBUHEPA	OL Argentina N = 200	October 30, 2020	Adult patients with COVID-19	NCT04530578
Low-molecular-weight heparin	NA	OL Egypt N = 50	October 31, 2020	Hospitalized adult patients with COVID-19 pneumonia	NCT04584580
Enoxaparin prophylactic dose and heparin SC, or enoxaparin intermediate dose and heparin infusion	IMPROVE-COVID	OL US N = 100	November 2020	Hospitalized adult patients with COVID-19	NCT04367831
Povidone iodine, chlorhexidine gluconate, hydrogen peroxide, or normal saline	NA	DB US N = 60	November 2020	Hospitalized adult patients with COVID-19	NCT04603794

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Valsartan	PRAETORIAN-COVID	DB, PC Netherlands N = 651	December 2020	Hospitalized adult patients with COVID-19	NCT04335786
Aerosolized 13-cis-retinoic acid (isotretinoin) with inhaled testosterone	NA	OL Egypt N = 1,000	December 2020	Hospitalized adult patients with COVID-19	NCT04623385
Sodium bicarbonate	NA	OL US N = 40	January 2021	Hospitalized adult patients with COVID-19	NCT04530448
Vitamin D	NA	DB, PC Belgium N = 100	January 31, 2021	Hospitalized adult patients with COVID-19	NCT04636086
Rivaroxaban	CARE	MC, OL Brazil N = 1,000	February 28, 2021	Adult patients with COVID-19 at risk for complications	NCT04757857
Distilled water, povidone-iodine, hydrogen peroxide, cetylpyridinium chloride, or sodium hypochlorite mouth rinses	NA	DB Saudi Arabia N = 120	February 28, 2021	Adult patients with COVID-19	NCT04721457
Rivaroxaban followed by enoxaparin or unfractionated heparin	ACTION	OL Brazil N = 615	March 2021	Hospitalized adult patients with COVID-19	NCT04394377
Cyclosporine	NA	OL Spain N = 120	March 2021	Hospitalized adult patients with COVID-19	NCT04392531
Tetrandrine	TT-NPC	OL China N = 60	March 1, 2021	Adult patients with mild and severe SARS-CoV-2 pneumonia	NCT04308317
Pioglitazone	NA	OL Spain N = 76	March 10, 2021	Adult patients with type 2 diabetes mellitus and COVID-19	NCT04535700
Early or late dexamethasone	NA	OL Egypt N = 300	April 1, 2021	Adult patients with mild-to-moderate COVID-19	NCT04528329

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Early or late dexamethasone	NA	OL Egypt N = 450	April 1, 2021	Adult patients with mild and moderate COVID-19	NCT04530409
Prophylactic or intermediate dose enoxaparin	NA	MC, OL US N = 170	April 16, 2021	Hospitalized adult patients with COVID-19	NCT04360824
Heparin (nebulized)	INHALE-HEP	DB, PC US N = 50	May 1, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04723563
Vitamin D (cholecalciferol)	CARED	DB, PC Argentina N = 1,264	May 15, 2021	Hospitalized adult patients with COVID-19	NCT04411446
Dexamethasone	NA	OL US N = 300	May 21, 2021	Adult patients with COVID-19	NCT04707534
Ibuprofen	LIBERATE	MC, DB UK N = 230	May 25, 2021	Hospitalized adult patients with confirmed or suspected SARS-CoV-2 and acute hypoxemic respiratory failure	NCT04334629
Colchicine	NA	OL Egypt N = 250	May 25, 2021	Adult patients with COVID-19	NCT04818489
Intermediate dose prophylaxis (enoxaparin sodium or unfractionated heparin or fondaparinux) or therapeutic dose anticoagulation (enoxaparin sodium or unfractionated heparin or fondaparinux or argatroban)	IMPACT	OL US N = 186	June 2021	Critically ill adult patients with COVID-19	NCT04406389
Pioglitazone	PIOQ8	DB, PC Multi-country N = 1,506	June 29, 2021	Diabetic adult patients (Type 2) with COVID-19	NCT04604223
Angiotensin receptor blockers (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan)	CLARITY	SB, PC Multi-country N = 1,500	June 30, 2021	Adult patients with SARS-CoV-2 infection	NCT04394117

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Dexamethasone	HIGHLOWDEXA	OL Spain N = 198	June 30, 2021	Hospitalized adults with respiratory failure caused by COVID-19 needing oxygen therapy	NCT04726098
Bamlanivimab	B-EPIC	OL Canada N = 576	June 30, 2021	Adult patients with SARS-CoV-2 infection	NCT04796402
Apixaban	APOLLO	DB, PC Brazil N = 1,000	August 2021	Adult outpatients with COVID-19 at risk for thrombosis	NCT04746339
Lenalidomide (low dose)	GETAFE	DB, PC Spain N = 120	August 31, 2021	Adult patients (≥ 60 years old) with mild-to- moderate signs of COVID-19	NCT04361643
Budesonide	NA	OL Multi-country N = 300	August 31, 2021	Hospitalized adult patients with COVID-19	NCT04355637
Heparin (prophylactic dose and therapeutic dose) with or without a P2Y12 inhibitor	ACTIV-4	OL, MC Multi-country N = 2,000	September 2021	Hospitalized adult patients with COVID-19	NCT04505774
Palmitoylethanolamide	NA	OL Italy N = 40	November 2021	Hospitalized adult patients with interstitial pneumonia due to COVID-19	NCT04568876
Enoxaparin (various doses)	COVI-DOSE	OL France N = 602	November 2021	Hospitalized adult patients with COVID-19	NCT04373707
Famotidine	CDFCOV19	DB, PC US N = 150	November 1, 2021	Adult patients with probable COVID-19 based on symptoms	NCT04565392
Vitamin D or zinc	NA	DB, PC India N = 700	November 30, 2021	Adult patients with COVID-19	NCT04641195
Enoxaparin prophylactic dose or full dose, or apixaban	FREEDOM COVID	OL Multi-country N = 3,600	December 2021	Hospitalized adult patients with COVID-19	NCT04512079

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Dexamethasone or methylprednisolone	NA	OL Spain N = 290	December 1, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04780581
Ivermectin and/or doxycycline	NA	DB, PC US N = 150	December 28, 2021	Adult (≥ 65 years old) residents of a nursing home or long-term care facility who have COVID-19 and are at high-risk	NCT04729140
Linagliptin	NA	OL US N = 20	December 30, 2021	Adult patients with type 2 diabetes and mild or moderate COVID-19	NCT04341935
Vitamin D	VitD-COVID19	DB, PC US N = 140	December 31, 2021	Adults (≥ 50 years old) with COVID-19	NCT04482673
Tenecteplase low dose	NA	DB, PC US N = 45	December 31, 2021	Adult patients with COVID-19 with acute pulmonary embolism	NCT04558125
Heparin	NA	DB, PC US N = 50	December 31, 2021	Hospitalized adult patients with COVID-19	NCT04397510
Ruconest	NA	DB, PC US N = 40	January 2022	Adult patients recovered from COVID-19, and experiencing neurological symptoms including fatigue	NCT04705831
Dexamethasone	COPPER	OL The Netherlands N = 2,000	February 2022	Adult patients with COVID-19	NCT04746430
NEW Dexamethasone	ROIDS-Dose	OL US N = 142	March 19, 2022	Adult patients with COVID-19	NCT04834375
Dexamethasone	REMED	MC, OL Czech Republic N = 300	March 31, 2022	Hospitalized adult patients with COVID-19 and ARDS	NCT04663555

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Phase III					
Azithromycin	AMBU-COVID	OL France N = 64	June 2020	Adult outpatients with non-severe symptoms of COVID-19	NCT04371107
Tacrolimus and methylprednisolone	TACROVID	OL Spain N = 84	June 1, 2020	Patients with severe lung injury secondary to COVID-19	NCT04341038
Favipiravir	NA	MC, DB, PC Italy N = 100	July 2020	Adult patients with moderate COVID-19	NCT04336904
Neurokinin 1 receptor antagonist	NA	DB Pakistan N = 100	July 15, 2020	Hospitalized adult patients with severe or critical COVID-19 infection	NCT04468646
Bromhexine and spironolactone	BISCUIT	OL Russian Federation N = 80	July 18, 2020	Hospitalized adult patients with mild and severe COVID-19	NCT04424134
Favipiravir	NA	OL, MC Russian Federation N = 168	July 29, 2020	Adult patients with mild-to-moderate COVID-19 without respiratory failure	NCT04501783
Azithromycin with or without amoxicillin-clavulanate	AziA	MC, OL France N = 104	July 30, 2020	Hospitalized adult patients with COVID-19 pneumonia in a non-intensive care unit	NCT04363060
Sarilumab	NA	Adaptive, MC, DB, PC Multi-country ^b N = 420	July 30, 2020	Hospitalized adult patients with severe or critical COVID-19	NCT04327388
Favipiravir	NA	MC, DB, PC Multi-country N = 256	August 2020	Adult patients with moderate COVID-19	NCT04425460
Vitamin D (ergocalciferol) low dose or high dose	NA	DB Canada N = 64	August 2020	Adult inpatients and outpatients with COVID-19	NCT04385940 HC Control No. 240943
Tradipitant	ODYSSEY	DB, PC US N = 300	August 1, 2020	Adult patients with severe or critical COVID-19	NCT04326426

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Tocilizumab	EMPACTA	MC, DB, PC Multi-country N = 379	August 18, 2020	Hospitalized adult patients with COVID-19 pneumonia	NCT04372186 Related article
Chlorpromazine	ReCoVery	MC, SB France N = 40	August 30, 2020	Hospitalized adult patients with moderate COVID-19	NCT04366739
Imatinib mesylate	NA	OL Egypt N = 30	September 2020	Hospitalized adult patients with moderate-to-severe COVID-19-induced pneumonia	NCT04422678
Tocilizumab or deferoxamine	TRONCHER	MC, OL Tunisia N = 260	September 4, 2020	Hospitalized adult patients in intensive care unit	NCT04361032
Hydrocortisone	COVID STEROID	DB Denmark N = 1,000	September 10, 2020	Hospitalized adult patients with COVID-19 and severe hypoxia	NCT04348305
Azithromycin	ATOMIC2	MC, OL UK N = 800	September 13, 2020	Adult outpatients with COVID-19	NCT04381962
Favipiravir or oseltamivir	NA	OL Indonesia N = 100	September 30, 2020	Adult patients with COVID-19	NCT04558463
Prasugrel hydrochloride	PARTISAN	MC, DB, PC Italy N = 128	October 2020	Hospitalized adult patients with severe COVID-19 pneumonia	NCT04445623
Tocilizumab or methylprednisolone	NA	OL Malaysia N = 310	October 31, 2020	Hospitalized adult patients with moderate COVID-19 at risk for complications	NCT04345445
Dexamethasone or methylprednisolone	NA	OL Bangladesh N = 60	November 5, 2020	Hospitalized adult patients (20 to 80 years old) with moderate-to-severe COVID-19	NCT04499313
Dornase alpha	COVIDORNASE	MC, OL France N = 100	November 21, 2020	Hospitalized adult patients with ARDS due to COVID-19	NCT04355364

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Budesonide	COVIDORL	MC, SB, PC France N = 120	November 24, 2020	Adult patients with persistent hyposmia related to SARS-CoV-2 infection	NCT04361474
Enoxaparin	RAPID- BRAZIL	OL Brazil N = 462	November 30, 2020	Hospitalized adult patients with COVID-19 and with low oxygen saturation	NCT04444700
Prednisone	PREDCOVID	SB Chile N = 184	November 30, 2020	Non-critical adult patients with COVID-19 pneumonia	NCT04451174
Prednisone or hydrocortisone hemisuccinate	CORTICOVIDHUGO	SB France N = 210	December 2020	Hospitalized adult patients with COVID-19 pneumonia on oxygen therapy	NCT04359511
Methylprednisolone	CORTIVID	DB Spain N = 72	December 2020	Hospitalized adult patients with COVID-19	NCT04438980
Doxycycline	DYNAMIC	MC, DB, PC France N = 330	December 1, 2020	Adult patients (> 45 years old) with SARS-CoV-2 infection	NCT04371952
Anakinra or siltuximab or tocilizumab or in combination	COV-AID	MC, OL Belgium N = 342	December 18, 2020	Adult patients with acute hypoxic respiratory failure and systemic cytokine release syndrome due to COVID-19	NCT04330638
Pulsed inhaled nitric oxide (INOpulse)	COViNOX	DB, PC US N = 500	December 28, 2020	Hospitalized adult patients with mild to moderate COVID-19	NCT04421508
Colchicine or interferon-beta or Aspirin or rivaroxaban	ACTCOVID-19	OL Multi-country ^b N = 4,000	December 31, 2020	Adult patients with COVID-19	NCT04324463 HC Control No. 238157
Methylprednisolone or heparin or both in combination	NA	OL Brazil N = 268	December 31, 2020	Adult patients with COVID-19	NCT04485429
Dexamethasone (high dose)	NA	MC, OL Argentina N = 284	December 31, 2020	Adult patients with ARDS due to COVID-19	NCT04395105

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Enoxaparin	ETHIC	OL, MC Country NR N = 1,370	January 2021	Adult patients (≥ 55 years old) with COVID-19 symptoms	NCT04492254
Anakinra	NA	DB US N = 30	January 2021	Hospitalized adult patients with SARS-CoV-2 infection with markers of cytokine storm syndrome	NCT04362111
Niclosamide	NICLONEX	DB, PC Turkey N = 200	January 30, 2021	Hospitalized adult patients with COVID-19	NCT04558021
Vitamin D (cholecalciferol)	NA	OL Mexico N = 40	February 2021	Pediatric patients (1 month to 17 years old) hospitalized with COVID-19	NCT04502667
Azithromycin, paracetamol, and rivaroxaban with or without ivermectin	NA	OL Mexico N = 62	February 2, 2021	Adult patients with COVID-19, with type 2 diabetes mellitus, systemic arterial hypertension, obesity, or who are overweight	NCT04673214
Nintedanib	NINTECOR	DB, PC France N = 250	March 2021	Adult patients with SARS-CoV-2–induced pulmonary fibrosis and a history of hospitalization due to COVID-19	NCT04541680
Lenzilumab	NA	DB, PC Multi-country N = 520	March 2021	Hospitalized adult patients with severe and critical COVID-19 pneumonia	NCT04351152
Rivaroxaban	PREVENT-HD	MC, DB, PC US N = 4,000	March 3, 2021	Adult outpatients with COVID-19	NCT04508023
Enoxaparin	NA	MC, OL Switzerland N = 1,000	March 14, 2021	Adult outpatients (≥ 50 years old) with COVID-19	NCT04400799
Dipyridamole and Aspirin	ATTAC-19	OL US N = 132	March 15, 2021	Hospitalized adult patients with COVID-19	NCT04410328

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Atorvastatin, nicorandil, l-arginine, folic acid, or vitamin B complex	LAUMCRH	OL Lebanon N = 70	March 20, 2021	Critically ill, hospitalized adult patients with COVID-19	NCT04813471
Proxalutamide	NA	DB, PC Brazil N = 590	March 22, 2021	Hospitalized adult patients with COVID-19	NCT04728802
Sitagliptin	SIDIACO	OL Italy N = 170	March 30, 2021	Hospitalized adult patients with COVID-19 and type 2 diabetes	NCT04365517
Colchicine	ECLA PHRI COLCOVID	OL Argentina N = 1,200	March 30, 2021	Hospitalized adult patients with moderate-to-severe COVID-19	NCT04328480
Favipiravir	PIONEER	OL UK N = 500	March 31, 2021	Hospitalized adult patients with suspected or confirmed COVID-19	NCT04373733
Lopinavir-ritonavir	CORIPREV-LR	OL Canada N = 1,220	March 31, 2021	Patients (≥ 6 months old) with COVID-19 symptoms	NCT04321174 HC Control No. 237350
Enoxaparin high dose or low dose	COVID-HEP	OL, SB Switzerland N = 200	March 31, 2021	Hospitalized adult patients with severe COVID-19	NCT04345848
Methylprednisolone or dexamethasone	MEDEAS	OL Rome N = 680	March 31, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04636671
Favipiravir	NA	MC, DB, PC Kuwait N = 780	March 31, 2021	Adult patients (21 to 80 years old) with moderate-to-severe COVID-19 hospitalized or quarantined in an institutional quarantine facility	NCT04529499
Ixekizumab or aldesleukin or colchicine	STRUCK	OL Brazil N = 60	March 31, 2021	Hospitalized adult patients with severe COVID-19	NCT04724629
Anakinra	SAVE-MORE	DB, PC Multi-country N = 606	March 31, 2021	Hospitalized adult patients with COVID-19	NCT04680949

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Nicotine patch	NICOVID-REA	DB, PC France N = 220	April 2021	Hospitalized adult patients with COVID-19 in intensive care unit	NCT04598594
Nitazoxanide	NA	MC, DB, PC Brazil N = 380	April 2021	Hospitalized adult patients with COVID-19	NCT04423861
Methylprednisolone	NA	MC, DB Italy N = 260	April 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04673162
Dapagliflozin	DARE-19	MC, DB, PC Multi-country ^b N = 1,250	April 2021	Hospitalized adult patients with mild-to-moderate COVID-19	NCT04350593 HC Control No. 240352
Fenofibrate	FENOC	OL Israel N = 50	April 1, 2021	Hospitalized adult patients with COVID-19	NCT04661930
Intermediate dose enoxaparin/ unfractionated heparin or standard prophylactic dose enoxaparin/ unfractionated heparin or atorvastatin	INSPIRATION	MC, OL, PC Iran N = 600	April 7, 2021	Critically ill hospitalized adult patients with COVID-19 admitted to ICU	NCT04486508
Famotidine	NA	OL Bangladesh N = 200	April 10, 2021	Patients (16 to 80 years old) with COVID-19	NCT04504240
Enoxaparin	HEP-COVID	MC, DB US N = 308	April 26, 2021	Hospitalized adult patients with COVID-19	NCT04401293
Rivaroxaban	COVID-PREVENT	MC, OL Germany N = 400	April 30, 2021	Hospitalized adult patients with moderate-to-severe COVID-19	NCT04416048
DAS 181	NA	DB, PC Multi-country N = 274	April 30, 2021	Hospitalized adult patients with severe COVID-19	NCT03808922
Rivaroxaban	MICHELLE	OL Brazil N = 320	April 30, 2021	Adult patients with COVID-19 and at an increased risk of VTE, and discharged from the hospital	NCT04662684

Experimental arm		Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
NEW	Ivermectin	NA	DB, PC Paraguay N = 400	April 30, 2021	Adult outpatients with non-severe COVID-19	NCT04834115
	Ravulizumab	NA	OL Multi-country N = 270	May 2021	Hospitalized adult patients with severe COVID-19 pneumonia	NCT04369469
	Novaferon	NCTT-005	DB, PC Countries NR N = 385	May 2021	Hospitalized adult patients with COVID-19	NCT04708158
	Ravulizumab	NA	OL US N = 32	May 2021	Hospitalized adult patients with COVID-19 and thrombotic microangiopathy	NCT04570397
	Bucillamine	NA	MC, DB, PC US N = 1,000	May 1, 2021	Adult patients with mild-to-moderate COVID-19	NCT04504734
	Colchicine	NA	OL Pakistan N = 102	May 9, 2021	Hospitalized adult patients with COVID-19	NCT04667780
	Baricitinib	COV-BARRIER	MC, DB, PC Multi-country N = 1,400	May 19, 2021	Hospitalized adult patients with COVID-19	NCT04421027
	Atorvastatin, L-arginine, folic acid, nicorandil, and nebivolol	MEDIC-LAUMC	DB, PC Lebanon N = 80	May 31, 2021	Hospitalized adult patients with COVID-19	NCT04631536
	Edoxaban (or high dose LMWH) and low dose LMWH	HERO-19	DB Germany N = 172	May 31, 2021	Hospitalized adult patients with COVID-19	NCT04542408
	Bemiparin	BEMICOP	OL Spain N = 164	May 31, 2021	Hospitalized adult patients with mild or moderate COVID-19 pneumonia	NCT04604327
Enoxaparin	EMOS-COVID	OL Italy N = 300	May 31, 2021	Hospitalized adult patients with COVID-19-related pneumonia with moderate-to-severe respiratory failure	NCT04646655	

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
FOY-305	NA	MC, DB, PC Japan N = 110	May 31, 2021	Adult patients with COVID-19	NCT04657497
Enoxaparin (high and low doses)	COVID-19 HD	MC, OL Italy N = 300	June 2021	Hospitalized adult patients with severe COVID-19 pneumonia and coagulopathy	NCT04408235
Favipiravir	NA	OL Hungary N = 150	June 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04600999
Losmapimod	LOSVID STUDY	DB, PC Multi-country N = 410	June 2021	Hospitalized adult patients (≥ 50 years old) with COVID-19	NCT04511819
Isotretinoin	NA	OL Egypt N = 10,000	June 2021	Hospitalized adult patients with COVID-19, admitted to ICU due to severe respiratory failure	NCT04353180
N-acetylcysteine	NA	DB Egypt N = 60	June 2021	Hospitalized adult patients with COVID-19	NCT04792021
Enisamium iodide	NA	MC, DB, PC Ukraine N = 700	June 1, 2021	Hospitalized adult patients with COVID-19	NCT04682873
Tinzaparin	PROTHROMCOVID	OL Spain N = 600	June 1, 2021	Hospitalized adult patients with high risk of thrombosis admitted with COVID-19 pneumonia	NCT04730856
SNG001	SPRINTER	DB, PC Multi-country N = 610	June 1, 2021	Hospitalized adult patients due to moderate COVID-19	NCT04732949
AZD7442	TACKLE	DB, PC Multi-country N = 1,700	June 30, 2021	Adult outpatients with COVID-19	NCT04723394
Losartan	ARBs CORONA II	MC, OL Multi-country ^b N = 1,372	June 30, 2021	Hospitalized adults with COVID-19	NCT04606563 HC Control No: 243532

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Enoxaparin with or without methylprednisolone	STAUNCH -19	MC, OL Italy N = 210	June 30, 2021	Hospitalized adults with critically ill pneumonia from COVID-19	NCT04528888
Ivermectin	NA	DB, PC US N = 200	June 30, 2021	Adult outpatients with highly suspicious symptoms of COVID-19	NCT04530474
Linagliptin	NA	OL Israel N = 100	June 30, 2021	Diabetic adult patients (Type 2) with COVID-19	NCT04371978
Carrimycin	NA	MC, DB, PC Multi-country N = 300	June 30, 2021	Hospitalized patients with severe COVID-19	NCT04672564
Vitamin D3	VIVID	DB, PC US N = 2,700	June 30, 2021	Adult patients (≥ 30 years old) with COVID-19	NCT04536298
NEW Dexamethasone	EARLYDEXCoV2	MC, OL Spain N = 126	June 30, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04836780
Azvodine	NA	DB, PC Brazil N = 342	July 2021	Hospitalized adult patients with COVID-19	NCT04668235
Almitrine	AIRVM-COVID	DB, PC France N = 212	July 2021	Hospitalized adult patients with COVID-19	NCT04357457
Fluvoxamine	Stop Covid 2	DB, PC Multi-country ^b N = 1,100	July 2021	Adult (≥ 30 years old) outpatients with COVID-19	NCT04668950 HC Control No. 246471
BACTEK-R (MV130)	NA	OL Dominican Republic N = 100	July 1, 2021	Hospitalized patients with non-severe pneumonia due to COVID-19	NCT04363814
Acetylsalicylic acid	Asperum	MC, DB, PC Italy N = 204	July 1, 2021	Hospitalized patients with pneumonia due to COVID-19	NCT04808895

Experimental arm		Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
NEW	Spironolactone and dexamethasone	SPIDEX-II	OL Russian Federation N = 440	July 8, 2021	Hospitalized patients with moderate-to-severe COVID-19	NCT04826822
	Eicosapentaenoic acid	NA	DB, PC Switzerland N = 284	July 13, 2021	Hospitalized patients with non-severe pneumonia due to COVID-19	NCT04335032
	Colchicine	COLCOVID19	OL Colombia N = 128	July 15, 2021	Hospitalized adult patients with COVID-19	NCT04539873
	Pacritinib	NA	MC, DB, PC US N = 364	July 31, 2021	Hospitalized patients with severe COVID-19 with or without cancer	NCT04404361
	Apixaban	NA	MC, DB, PC US N = 5,320	August 2021	Hospitalized adult patients with COVID-19	NCT04650087
	Favipiravir	PRESECO	DB, PC US N = 826	August 2021	Adult outpatients with mild-to-moderate COVID-19	NCT04600895
	Fostamatinib	NA	MC, DB, PC Multi-country N = 308	August 2021	Hospitalized patients with COVID-19, and without respiratory failure	NCT04629703
	Sphenopalatine ganglion block with local anaesthetic (lidocaine and ropivacaine)	NA	DB, PC Denmark N = 60	August 2021	Adult patients with moderate-to-severe headache during or maximum 4 weeks after COVID-19 diagnosis	NCT04636034
	Enoxaparin (low dose or high dose)	X-COVID 19	MC, OL Italy N = 2,712	August 2021	Hospitalized adult patients with SARS-CoV-2 infection	NCT04366960
	Novaferon (aerosolized)	NOVATION-1	DB, PC Countries NR N = 914	August 2021	Hospitalized patients with COVID-19	NCT04669015 HC Control No. 246575
	Molixan	NA	MC, DB, PC Russia N = 330	August 19, 2021	Hospitalized adult patients with severe COVID-19	NCT04780672

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Colchicine	COLCHI-COVID	OL Spain N = 954	August 25, 2021	Adult outpatients (≥ 60 years old) with COVID-19 and at high risk of pulmonary complication due to COVID-19	NCT04416334
N-Acetylcysteine	INFECT-19	DB, PC Saudi Arabia N = 1,180	August 30, 2021	Hospitalized patients with COVID-19 who are on oxygen supplement	NCT04455243
TY027	NA	MC, DB, PC Singapore N = 1,305	August 31, 2021	Hospitalized adult patients (≥ 21 years old) with symptomatic COVID-19 infection	NCT04649515
Favipiravir	NA	MC, OL Malaysia N = 500	August 31, 2021	Adult patients (≥ 50 years old) with mild to moderate COVID-19 infection	NCT04818320
Apixaban or Aspirin	NA	MC, DB, PC US N = 7,000	September 2021	Adult (40 to 79 years old) with COVID-19	NCT04498273
Montelukast	COSMO	DB, PC Canada N = 600	September 2021	Adult (≥ 40 years old) with COVID-19	NCT04389411
Dexamethasone	COVIDSTEROID2	DB Multi-country N = 1,000	September 17, 2021	Hospitalized adult patients with COVID-19	NCT04509973
Azithromycin	ACTION	DB, PC US N = 2,271	September 30, 2021	Adult outpatients with COVID-19	NCT04332107
Brexanolone	NA	DB, PC US N = 100	October 2021	Hospitalized adult patients with COVID-19, and a presumptive diagnosis of ARDS	NCT04537806
Prednisolone or dexamethasone	COPreDex	MC, OL France N = 220	October 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04765371
Vitamin D3, vitamin C with zinc, or vitamin K2 with vitamin D	NA	DB, PC Canada N = 200	October 2021	Adult outpatients with COVID-19	NCT04780061

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Edoxaban and/or colchicine	CONVINCE	OL Switzerland N = 420	October 1, 2021	Adult outpatients with COVID-19	NCT04516941
Ethanol (vapor inhalation) with Aspirin	NA	OL Egypt N = 80	October 1, 2021	Hospitalized adult patients (20 to 60 years old) with COVID-19	NCT04554433
Heparin (therapeutic or prophylactic dose) with or without tocilizumab	HEPMAB	OL Brazil N = 308	October 20, 2021	Hospitalized adult patients with COVID-19	NCT04600141
Colchicine and rosuvastatin	COLSTAT	OL US N = 466	October 30, 2021	Hospitalized patients with COVID-19	NCT04472611
Adalimumab	COMBAAT	MC, DB, PC Countries NR N = 1,444	November 2021	Adults (40 to 80 years old) with COVID-19	NCT04705844
Vitamin C	LOVIT-COVID	DB, PC Canada N = 800	November 2021	Hospitalized adult patients with COVID-19	NCT04401150 HC Control no: 239705
NEW Cyproheptadine	NA	OL Canada N = 200	November 1, 2021	Hospitalized adult patients with severe COVID-19	NCT04820751
Vitamin D	NA	DB, PC Spain N = 108	November 30, 2021	Hospitalized adult patients with COVID-19 and vitamin D deficiency	NCT04621058
Interferon alpha or selinexor or lenzilumab	C-SMART	SMART, DB Australia N = 2,882	December 2021	(Treatment arms only; also see Table 3) Hospitalized adult patients with COVID-19 and a hematological or solid tumour who are currently receiving cancer-related treatment or have received treatment within the last 12 months	NCT04534725

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Nicotine patches	NICOVID	DB, PC France N = 220	December 2021	Hospitalized adults with COVID-19	NCT04608201
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers	COVID-RASi	OL Canada N = 1,155	December 2021	Older adult patients (≥ 65 years old) with COVID-19 and at high risk for cardiovascular diseases	NCT04591210 HC Control No. 244591
CPI-006	NA	MC, DB, PC Multi-country ^b N = 1,000	December 30, 2021	Hospitalized adults with mild-to-moderate COVID-19 symptoms	NCT04734873 HC Control No. 249442
Tocilizumab	COVIDSTORM	OL Finland N = 90	December 31, 2021	Hospitalized adults in the inflammatory phase of COVID-19	NCT04577534
Lidocaine	LidoCovid	DB, PC France N = 100	December 31, 2021	Hospitalized adults admitted to the intensive care unit due to COVID-19	NCT04609865
Tocilizumab	ARCHITECTS	DB, PC US N = 300	December 31, 2021	Hospitalized adults with severe COVID-19	NCT04412772
Vitamin C	LOVIT	DB, PC Canada N = 800	December 31, 2021	Hospitalized adults admitted to the intensive care unit due to COVID-19	NCT03680274 HC Control No: 237164
Camostat mesylate	CAMOVID	DB, PC France N = 596	January 2022	Adult patients with COVID-19 and at increased risk of developing severe COVID-19	NCT04608266
Isavuconazonium	Isavu-CAPA	DB, PC US N = 162	January 2022	Hospitalized patients with COVID-19	NCT04707703
NEW VERU-111	NA	MC, DB, PC Multi-country N = 300	January 5, 2022	Hospitalized patients with COVID-19 at high risk of ARDS	NCT04842747
Inhaled steroid (budesonide-formoterol)	INHASCO	OL France N = 436	January 13, 2022	Hospitalized patients with COVID-19	NCT04331054

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Sodium bicarbonate	NA	OL UK N = 80	January 31, 2022	Adult patients with COVID-19 who are admitted to a critical care unit with bladder catheter in situ	NCT04655716
NEW Bevacizumab	BEVA	OL France N = 174	February 2022	Hospitalized adult patients with severe hypoxemic COVID-19	NCT04822818
Fluvoxamine, metformin, or ivermectin	NA	MC, DB, PC Brazil N = 2,724	February 1, 2022	Adult patients with COVID-19 at increased risk of complications	NCT04727424
Apremilast or lanadelumab or zilucoplan	NA	DB Multi-country ^b N = 1,400	February 17, 2022	Hospitalized patients with COVID-19	NCT04590586 HC Control No. 242568
Heparin (various doses)	RAPID COVID COAG	OL Canada N = 462	March 2022	Hospitalized adult patients with SARS-CoV-2	NCT04362085 HC Control No: 238510
Ivermectin or Aspirin	PaTS-COVID	OL Gambia N = 1,200	March 2022	Patients (≥ 5 years old) with COVID 19 mild disease or moderate to severe pneumonia	NCT04703608
Sevoflurane	SevCov	DB Switzerland N = 64	March 31, 2022	Adult patients in ICU with COVID-19 and ARDS	NCT04355962
Montelukast	E-SPERANZA	DB, PC Spain N = 284	March 31, 2022	Adult patients with long COVID-19 and mild to moderate respiratory symptoms	NCT04695704
NEW Corticosteroids	CORE-COVID	DB, PC Multi-country ^b N = 1,526	April 2022	Adult patients with COVID-19	NCT04795583 HC Control No.: 249936

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Phase II/III					
Favipiravir	NA	DB, PC Bangladesh N = 50	July 2020	Adult patients with novel coronavirus	NCT04402203
Ivermectin	NA	OL Egypt N = 100	July 30, 2020	Adult patients with COVID-19	NCT04445311
Nitazoxanide	NA	DB, PC Brazil N = 300	September 2020	Adult outpatients (≥ 50 years old) with symptomatic SARS-CoV-2 infection	NCT04441398
Vidofludimus calcium (IMU-838)	NA	MC, DB, PC Multi-country N = 230	September 2020	Hospitalized adult patients with COVID-19	NCT04379271
LY3819253 and LY3832479	BLAZE -1	DB, PC Multi-country N = 4,000	September 20, 2020	Child and adult outpatients (≥ 12 years old) with mild to moderate COVID-19	NCT04427501 Related article
Pyridostigmine	PISCO	DB, PC Mexico N = 436	September 30, 2020	Hospitalized adult patients with pneumonia secondary to SARS-CoV-2 infection	NCT04343963
Chlorpromazine	NA	SC, SB, OL Egypt N = 100	October 2020	Adult patients with COVID-19	NCT04354805
Ivermectin and nitazoxanide	NA	DB Egypt N = 100	October 2020	Adult patients with SARS-CoV-2 infection	NCT04360356
Vitamin D (25-hydroxyvitamin D3)	NA	MC, DB, PC Iran N = 1,500	November 15, 2020	Treatment: Adult patients with COVID-19 Prevention: See Table 3	NCT04386850
Nitazoxanide	NA	SB, PC Argentina N = 135	November 15, 2020	Adult patients with mild COVID-19	NCT04463264
Cannabidiol	CANDIDATE	SC, DB, PC Brazil N = 104	November 16, 2020	Adult patients with mild or moderate COVID-19	NCT04467918

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Olokizumab	NA	MC, DB, PC US N = 376	November 16, 2020	Hospitalized adult patients with severe SARS-CoV-2 infection	NCT04452474
Reparixin	NA	OL Brazil N = 55	November 30, 2020	Hospitalized adult patients with COVID-19 pneumonia	NCT04794803
Anakinra	ANA-COVID-GEAS	MC, OL Spain N = 180	December 2020	Hospitalized adult patients with severe pneumonia due to SARS-CoV-2	NCT04443881
CT-P59	NA	DB, PC Republic of Korea N = 1,020	December 2020	Adult patients with mild to moderate COVID-19	NCT04602000
Favipiravir	NA	OL, PC Egypt N = 90	December 1, 2020	Children, adults, and older adult patients with COVID-19	NCT04351295
ABX464	MiR-AGE	DB, PC Multi-country N = 1,034	December 30, 2020	Adult inpatients or outpatients with SARS-CoV-2 infection	NCT04393038
Angiotensin-(1,7)	ATCO	Adaptive, DB, PC Belgium N = 60	December 30, 2020	Adult patients with COVID-19 requiring mechanical ventilation	NCT04332666
NA-831 alone or in combination with atazanavir or dexamethasone, and atazanavir with dexamethasone	NATADEX	DB US N = 525	December 31, 2020	Hospitalized adult patients with SARS-CoV-2	NCT04452565
Heparin	ATTACC	OL, MC Multi-country ^b N = 1,203	January 2021	Hospitalized adult patients with COVID-19	NCT04372589 HC Control No. 238691
RESP301 (nitric oxide)	NA	MC, OL UK N = 300	January 27, 2021	Hospitalized adult patients with COVID-19	NCT04460183
Dociparstat	NA	DB, PC US N = 525	February 2021	Hospitalized adult patients with severe COVID-19 and at high risk of respiratory failure	NCT04389840

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
INB03	NA	MC, DB, PC US N = 366	February 2021	Adult patients with severe COVID-19 who have high-risk factors for complication	NCT04370236
Ivermectin (nasal spray)	NA	OL Egypt N = 150	February 20, 2021	Adult patients with COVID-19	NCT04716569
Ciclesonide	CONTAIN	DB, PC Canada N = 454	February 25, 2021	Symptomatic adult patients with mild COVID-19	NCT04435795 HC Control No. 239123
Atazanavir or daclatasvir with or without sofosbuvir	REVOLUTION	MC, DB, PC MAMS Brazil N = 1,005	February 28, 2021	Hospitalized adult patients with COVID-19	NCT04468087
Ivermectin	IVERCORCOVID19	DB, PC Argentina N = 500	February 28, 2021	Adult patients with COVID-19	NCT04529525
Emtricitabine and tenofovir or colchicine or rosuvastatin	NA	OL Colombia N = 1,200	February 28, 2021	Hospitalized adult patients with COVID-19	NCT04359095
VIR-7831	COMET-ICE	MC, DB, PC Multi-country ^b N = 1,360	March 2021	Adult outpatients with COVID-19	NCT04545060 HC Control No. 244708
Amiodarone or verapamil	ReCOVvery-SIRIO	OL Poland N = 804	March 2, 2021	Hospitalized adult patients with COVID-19	NCT04351763
Lopinavir-ritonavir alone or in combination with telmisartan or atorvastatin	INTENSE-COV	MC, OL Cote D'Ivoire N = 294	March 26, 2021	Adult patients with SARS-CoV-2 infection	NCT04466241
Sarilumab	CORIMUNO-SARI	MC, OL France N = 239	March 27, 2021	Hospitalized adult patients with moderate or severe COVID-19 pneumonia	NCT04324073
Nafamostat mesylate	NA	OL China N = 84	March 30, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04418128
Azoximer bromide	NA	MC, DB, PC Multi-country N = 394	April 2021	Hospitalized adult patients with COVID-19	NCT04381377

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Unfractionated heparin	INHALE-HEP	DB Multi-country N = 712	April 1, 2021	Hospitalized adult patients with COVID-19	NCT04635241
Sofosbuvir or daclatasvir	NA	DB Egypt N = 100	April 1, 2021	Adult patients with COVID-19	NCT04497649
Tenofovir and emtricitabine	AR0-CORONA	OL France N = 180	April 1, 2021	Adult outpatients with COVID-19	NCT04685512
REGN10933 and REGN10987	NA	DB, PC Multi-country N = 6,420	April 10, 2021	Child, adult, and older adult patients with COVID-19	NCT04425629
Meplazumab	NA	MC, DB, PC China N = 456	April 28, 2021	Hospitalized adult patients with COVID-19	NCT04586153
Anakinra	NA	OL Qatar N = 80	April 30, 2021	Hospitalized adult patients with COVID-19, and presence of respiratory distress and pneumonia	NCT04643678
rNAPc2 (AB201) or heparin	ASPEN-COVID-19	MC, DB US N = 100	April 30, 2021	Hospitalized adult patients with COVID-19 and elevated D-dimer levels	NCT04655586
NEW B1767551	NA	DB, PC Countries NR N = 1,440	May 22, 2021	Adult outpatients with mild-to-moderate COVID-19	NCT04822701
SCTA01	NA	DB, PC China N = 560	May 25, 2021	Hospitalized adult patients with COVID-19	NCT04683328
IFX-1	NA	MC, DB, PC Multi-country N = 390	May 31, 2021	Adult patients with severe COVID-19 pneumonia	NCT04333420

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Nicosamide	NA	DB, PC US N = 436	June 2021	Adult patients with moderate and severe COVID-19 infection	NCT04603924
Metformin	MET-Covid	DB, PC US N = 750	June 2021	Adult outpatients (30 to 85 years old) with COVID-19	NCT04510194
Opaganib	NA	DB, PC Multi-country N = 464	June 2021	Adult patients with COVID-19 pneumonia	NCT04467840
Losartan	COVIDMED	MC, DB, PC US N = 100	June 1, 2021	Hospitalized adult patients with COVID-19	NCT04328012
Molnupiravir	MK-4482-002	PC, DB Multi-country ^b N = 1,450	June 23, 2021	Adult outpatients with COVID-19	NCT04575597 HC Control No. 244315
Molnupiravir	MK-4482-001	PC, DB Multi-country ^b N = 1,300	June 27, 2021	Hospitalized adult patients with COVID-19	NCT04575584 HC Control No. 244159
SCTA01	NA	MC, DB, PC Multi-country N = 795	June 27, 2021	Hospitalized adult patients with severe COVID-19	NCT04644185
Aspirin or ivermectin	IVCOM	OL Uganda N = 490	June 30, 2021	Adult patients with moderate COVID-19 infection	NCT04768179
BIO101	COVA	DB, PC Multi-country N = 310	July 2021	Hospitalized adult patients (≥ 45 years old) with COVID-19	NCT04472728
Zavegepant (BHV-3500)	NA	DB, PC US N = 120	July 2021	Hospitalized adult patients with COVID-19	NCT04346615
Nafamostat mesylate or TD139	DEFINE	OL UK N = 60	July 3, 2021	Children and adult patients (≥ 16 years old) with COVID-19	NCT04473053
PTC299	FITE19	DB, PC, MC Multi-country N = 380	July 31, 2021	Hospitalized adult patients with COVID-19	NCT04439071

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Sofosbuvir and daclatasvir or ledipasvir	NA	OL Egypt N = 60	August 1, 2021	Children and adult patients with COVID-19	NCT0446 0443
BDB-001	NA	MC, OL Multi-Country N = 368	August 7, 2021	Adult patients with severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome	NCT04449588
Telmisartan or vitamins or ciclesonide or interferon beta-1b	COVERAGE	MC, OL, MAMS France N = 820	August 15, 2021	Outpatient elderly patients (≥ 50 years old) with symptomatic SARS-CoV-2 infection	NCT04356495
Aviptadil	AVICOVID-2	MC, DB, PC US N = 288	August 15, 2021	Patients (≥ 12 years old) with moderate and severe COVID-19 who have not yet developed respiratory failure	NCT04360096
Camostat	NA	OL UK N = 389	August 31, 2021	Adult outpatients (≥ 50 years old) with symptomatic SARS-CoV-2 infection	NCT04455815
Cannabidiol	NA	DB, PC US N = 422	September 2021	Hospitalized adult patients with COVID-19, with a history of, or at risk of, cardiovascular diseases	NCT04615949
Upamostat	NA	DB, PC US N = 310	September 2021	Adult outpatients with COVID-19	NCT04723537
NEW Favipiravir or ribavirin	NA	MC, OL Turkey N = 100	September 30, 2021	Adult outpatients with COVID-19	NCT04828564
Colchicine and prednisone	NA	OL Spain N = 144	October 2021	Hospitalized older adult patients (≥ 65 years old) with COVID-19	NCT04492358
Furosemide (nebulized)	FaST-1	DB Canada N = 640	October 1, 2021	Hospitalized adult patients with COVID-19	NCT04588792 HC Control No. 244310

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Pyronaridine-artesunate	PROVIDENCE	MC, DB, PC Philippines N = 402	October 15, 2021	Adult outpatients (≥ 19 years old) with COVID-19	NCT04701606
Sargramostim	NA	MC, DB, PC Japan N = 60	October 31, 2021	Hospitalized adult patients (≥ 20 to 80 years old) with COVID-19 pneumonia	NCT04642950
Nitazoxanide	C3-RCT	PC, DB South Africa N = 960	December 2021	Adult outpatients with COVID-19	NCT04523090
Nafamostat mesylate	RACONA	DB, PC Countries NR N = 256	December 2021	Hospitalized adult patients with COVID-19	NCT04352400
TJ003234	NA	MC, DB, PC US N = 384	December 2021	Hospitalized adult patients with severe COVID-19	NCT04341116
Favipiravir	Avi-Mild	MC, DB, PC Saudi Arabia N = 576	December 2021	Adult patients with mild COVID-19	NCT04464408
Mavrilimumab	NA	DB, PC Multi-country N = 588	December 2021	Hospitalized adult patients with severe COVID-19 pneumonia and hyperinflammation	NCT04447469
ADG20	STAMP	DB, PC US N = 1,728	December 2021	Adult outpatients with mild or moderate COVID-19	NCT04805671
Tempol (MBM-02)	NA	DB, PC US N = 310	December 30, 2021	Adult outpatients with COVID-19	NCT04729595
Hyperbaric oxygen	COVID-19-HBO	OL Multi-country N = 200	December 31, 2021	Adult patients with COVID-19	NCT04327505
Triazavirin	PHRUCov01	DB, PC South Africa N = 420	December 31, 2021	Hospitalized adult patients with mild-to-moderate COVID-19	NCT04581915
SCTA01	MAOP3	DB, PC China N = 690	January 1, 2022	High risk adult outpatients with COVID-19	NCT04709328

Experimental arm		Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
NP-120 (Ifenprodil)		NA	OL Multi-country ^b N = 682	January 2022	Hospitalized adult patients with COVID-19	NCT04382924 HC Control No. 238605
NEW	RESP301	PREVENT	OL United Kingdom N = 600	January 2022	Adults with mild-to-moderate COVID-19 symptoms	NCT04842331
Renin-angiotensin system inhibitors		SWITCH-COVID	OL Brazil N = 240	February 14, 2022	Hospitalized adult patients with COVID-19	NCT04493359
EDP1815 or dapagliflozin and ambrisentan		TACTIC-E	OL UK N = 1,407	February 15, 2022	Hospitalized adult patients (pre-ICU) with COVID-19	NCT04393246
NEW	Heparin (nebulized)	CHARTER-MT	DB US N = 300	April 2022	Hospitalized adult patients in ICU with severe COVID-19	NCT04545541
NEW	FP-025	NA	MC, DB, PC Countries NR N = 403	April 2022	Hospitalized patients with severe to critical COVID-19 with ARDS	NCT04750278

ARDS = acute respiratory distress syndrome; DB = double blind; HC = Health Canada; LMWH = low molecular weight heparin; hsCRP = high-sensitivity C-reactive protein; MC = multi-centre; OL = open label; MAMS = multi-arm multi-stage; NA = not applicable; NR = not reported; PC = placebo controlled; SARS-CoV2 = severe acute respiratory syndrome coronavirus 2; SB = single blind; SC = subcutaneous; SMART = sequential multiple arm randomised trial.

^a The date on which data collection is completed for all the primary outcome measures.

^b Includes Canada.

Table 3: Drugs to Prevent COVID-19: Ongoing Randomized Controlled Trials — April 2022 Estimated Primary Completion Date

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Pre-exposure prophylaxis or prevention					
Phase IV					
Icosapent ethyl	MITIGATE	OL US N = 16,500	August 7, 2021	Adults (≥ 50 years old) with no prior history of COVID-19, and established atherosclerotic cardiovascular disease	NCT04505098
Phase III					
Levamisole or isoprinosine or in combination	NA	OL Egypt N = 100	November 1, 2020	Healthy health care workers testing negative for COVID-19	NCT04360122
Emtricitabine-tenofovir alafenamide	CoviPrep	DB, PC Argentina N = 1,378	November 15, 2020	Healthy health care workers having a high transmission risk for COVID-19 and no prior diagnosis of SARS-CoV-2 infection	NCT04405271
Doxycycline and zinc	NA	MC, DB, PC Tunisia N = 1,100	February 1, 2021	Military health care workers	NCT04584567
NEW AZD7442	PROVENT	MC, DB, PC Multi-country N = 5,247	April 21, 2021	Medically stable adults who can benefit from passive immunization with antibodies	NCT04625725
High and low doses vitamin D	CORONAVIT	OL UK N = 6,200	June 30, 2021	Children and adults (≥ 16 years old)	NCT04579640

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Phase II/III					
Vitamin D (25-hydroxyvitamin D3)	NA	MC, DB, PC Iran N = 1,500	November 15, 2020	Prevention: Hospital health providers with a negative COVID-19 test Prevention: Close relative of a patient with COVID-19 Treatment: See Table 3	NCT04386850
Post-exposure prophylaxis					
Phase IV					
Nitazoxanide	PENTZ	DB, PC Argentina N = 456	April 30, 2021	Adults living in a household with a confirmed SARS-CoV-2 case	NCT04788407
Phase III					
Ivermectin	IverprofCovid19	MC, DB, PC Colombia N = 550	November 30, 2020	Health care workers at all levels of care	NCT04527211
Icosapent ethyl	PREPARE-IT	DB, PC Argentina N = 2,000	January 2021	Health care providers at risk of occupational exposure to COVID-19	NCT04460651
Bamlanivimab (LY3819253; LY-CoV555) with or without LY3832479	BLAZE-2	DB, PC US N = 5,000	March 8, 2021	Residents and facility staff in a skilled nursing or assisted living facility with at least one confirmed case of SARS-CoV-2	NCT04497987
Nitazoxanide	NA	MC, DB, PC US N = 1407	March 29, 2021	Health care workers at increased risk for direct occupational exposure to COVID-19	NCT04359680
Peginterferon beta-1a	ConCorD-19	OL Chile N = 1,240	April 2021	Adults with no previous history of confirmed SARS-CoV-2 diagnosis, living in a household with a confirmed SARS-CoV-2 case (first known diagnosis in the household).	NCT04552379

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
DWJ1248	NA	DB Countries NR N = 1,012	April 2021	Adults in self-isolation after contact with COVID-19 — confirmed patient	NCT04721535
REGN10933 and REGN10987	NA	DB, PC Multi-country N = 3,750	June 15, 2021	Children and adults (≥ 12 year old) with household contact with exposure to an individual with a diagnosis of SARS-CoV-2	NCT04452318
Nitazoxanide	NA	MC, DB, PC US N = 800	June 30, 2021	Residents (≥ 55 years old) of long-term care facilities	NCT04343248
NEW OM85 (Broncho-Vaxom)	COVIDRASP	OL Australia N = 59	June 30, 2021	Health care workers assessing and caring for patients with COVID-19	NCT04496245
Vitamin D3	PROTECT	DB, PC Canada N = 2,414	September 30, 2021	Health care workers at high risk of COVID-19 infection (working at COVID-designated or infected installations)	NCT04483635 HC Control No. 243196
Nicotine	NICOVID-PREV	DB, France N = 1,633	December 2021	Adults exposed to COVID-19	NCT04583410
Interferon alpha or selinexor or lenzilumab	C-SMART	SMART, DB Australia N = 2,882	December 2021	(Prevention arms only; also see Table 2) Adult patients with and without exposure to a COVID-19 case (2 arms) with a hematological or solid tumour and currently receiving cancer-related treatment or have received treatment within the last 12 months	NCT04534725
AZD7442	STORM CHASER	MC, DB, PC Multi-country N = 1,125	January 21, 2022	Adults exposed to an individual with COVID-19	NCT04625972

Experimental arm	Trial name	Study design, country, sample size	Estimated trial primary completion date ^a	Population	ClinicalTrials.gov reference
Phase II/III					
Tenofovir and emtricitabine	NA	MC, DB, PC Colombia N = 950	December 31, 2020	Health care professionals in direct care of patients in emergency rooms, general COVID-wards, or intensive care units	NCT04519125
Hypochlorous acid	NA	DB, PC Colombia N = 556	June 15, 2021	Health care professionals working in the hospital	NCT04684550

ARDS = acute respiratory distress syndrome; DB = double blind; MC = multi-centre; OL = open label; MAMS = multi-arm multi-stage trial; NA = not applicable; NR = not reported; PC = placebo controlled; SARS-CoV2 = severe acute respiratory syndrome coronavirus 2.

^a The date on which data collection is completed for all the primary outcome measures.

References

1. ClinicalTrials.gov. Bethesda (MD): U.S. National Library of Medicine; 2020: <https://clinicaltrials.gov/>. Accessed 2021 April 16.
2. CADTH COVID-19 evidence portal. *CADTH report archives*. Ottawa (ON): CADTH; 2020: <https://covid.cadth.ca/tag/cadth-report/>. Accessed 2021 April 16.
3. Government of Canada. Clinical trial search. 2020; <https://health-products.canada.ca/ctdb-bdec/index-eng.jsp>. Accessed 2021 April 16.

Appendix 1: Trials That Are No Longer Active

Table 4: Drugs to Treat COVID-19: Completed, Withdrawn, Terminated, or Suspended Randomized Controlled Trials

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Phase IV						
Tocilizumab	NA	OL Pakistan N = 93	June 12, 2020	Patients (16 to 85 years old) with COVID-19 associated cytokine release syndrome	NCT04730323 Completed	Not yet published
Dexamethasone	DEXA-COVID19	MC, OL Spain N = 19	June 19, 2020	Adult patients with moderate-to-severe ARDS due to COVID-19 and who are mechanically ventilated	NCT04325061 Terminated	NA
Ivermectin	NA	OL Pakistan N = 50	June 30, 2020	Adult patients with COVID-19	NCT04739410 Completed	Not yet published
Bromhexine	NA	OL Russian Federation N = 50	August 31, 2020	Medical personnel at risk of contracting COVID-19 (assisting patients with COVID-19)	NCT04405999 Completed	Not yet published
Famotidine	NA	MC, DB US N = 233	September 7, 2020	Hospitalized adult patients with COVID-19	NCT04370262 Completed	Not yet published
Sargramostim	SARPAC	OL Belgium N = 80	September 28, 2020	Adult patients with acute hypoxic respiratory failure due to COVID-19	NCT04326920 Completed	News
Sofosbuvir and ledipasvir or nitazoxanide	NA	OL Egypt N=240	October 30, 2020	Hospitalized patients (12 to 65 years old) with COVID-19	NCT04498936 Completed	Not yet published
Telmisartan	NA	OL Argentina N = 400	November 2, 2020	Hospitalized adult patients with COVID-19	NCT04355936 Completed	Commentary

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Zinc sulfate	NA	DB, PC N = 3	February 8, 2021	Adults (≥ 30 years old) outpatients with COVID-19	NCT04621461 Completed	NA
ACE Inhibitors	AECI-COVID	OL Multi-country N = 216	February 16, 2021	Adult patients with COVID-19	NCT04353596 Completed	Not published yet
Thiazide or thiazide-like diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers	CORONACION	OL Ireland N = 2,414	July 31, 2021	Adult patients (≥ 60 years old) with a diagnosis of hypertension and currently using ACEi or ARB, and not yet infected with COVID-19	NCT04330300 Suspended	NA
Budesonide with or without olfactory retraining	NA	OL Canada N = 0	December 10, 2021	Adult patients with hyposmia or anosmia immediately after upper respiratory viral illness (including COVID-19)	NCT04374474 Withdrawn	NA
Phase III						
Tocilizumab	COVACTA	MC, DB, PC Multi-country ^b N = 450	June 24, 2020	Hospitalized adult patients with severe COVID-19 pneumonia	NCT04320615 HC Control No. 237397 Completed	Pre-print Related article Related article
Levilimab	CORONA	MC, PC, DB Russian Federation N = 206	July 3, 2020	Hospitalized adult patients with severe COVID-19	NCT04397562 Completed	Not yet published
Tocilizumab	TOCIBRAS	OL Brazil N = 129	July 8, 2020	Adult patients with moderate-to-severe COVID-19	NCT04403685 Terminated	Published
Tocilizumab	NA	MC, DB, PC US N = 243	July 13, 2020	Hospitalized adult and older adult patients with severe COVID-19	NCT04356937 Completed	Published

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Dornase alfa (Tigerase)	NA	OL Russian Federation N = 100	July 20, 2020	Adult patients with moderate COVID-19	NCT04459325 Completed	Not yet published
Dexamethasone	CoDEX	MC, OL Brazil N = 299	July 22, 2020	Adult patients with moderate and severe ARDS due to SARS-CoV2	NCT04327401 Terminated	Published
Favipiravir	NA	OL Russian Federation N = 200	August 10, 2020	Hospitalized adult patients with moderate COVID-19	NCT04542694 Completed	Results posted on ClinicalTrials.gov
Ivermectin and doxycycline	NA	DB, PC Bangladesh N = 400	August 22, 2020	Adult patients with mid and moderate COVID-19	NCT04523831 Completed	Results posted on ClinicalTrials.gov
Ivermectin	NA	OL Turkey N = 66	September 2, 2020	Hospitalized adult patients with severe COVID-19 pneumonia	NCT04646109 Completed	Results posted on ClinicalTrials.gov
Canakinumab	CAN-COVID	MC, DB, PC Multi-country N = 451	September 16, 2020	Hospitalized patients (≥ 12 years old) with COVID-19–induced pneumonia and cytokine release syndrome	NCT04362813 Completed	Not yet published
Ruxolitinib	RUXCOVID	MC, DB, PC Multi-country ^b N = 432	October 17, 2020	Hospitalized patients (≥ 12 years old) with COVID-19–associated cytokine storm	NCT04362137 HC Control No.240395 Completed	Not yet published
Colchicine	COL-COVID	OL Spain N = 102	October 20, 2020	Hospitalized adult patients with SARS-CoV-2 infection confirmed within the first 48 hours after hospital admission	NCT04350320 Completed	Not yet published

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Anakinra	ANACONDA	MC, OL France N = 71	October 20, 2020	Hospitalized adult patients with COVID-19	NCT04364009 Terminated	NA
CD24Fc	SAC-COVID	MC, DB, PC US N = 243	October 20, 2020	Adult patients with severe COVID-19	NCT04317040 Completed	Not yet published
Mometasone furoate	NA	OL Egypt N = 100	October 25, 2020	Adult patients with COVID-19 and recent onset of anosmia or hyposmia	NCT04484493 Completed	Published
XC221	NA	MC, DB, PC Russian Federation N = 118	October 29, 2020	Adult patients with COVID-19	NCT04487574 Completed	Not yet published
Emapalumab or anakinra	NA	MC, OL Multi-country N = 16	November 13, 2020	Adult patients with SARS-CoV-2 infection	NCT04324021 Terminated	NA
Naproxen	ENCOVID	OL France N = 30	December 15, 2020	Hospitalized adult patients who are critically ill due to COVID-19	NCT04325633 Terminated	NA
Lopinavir-ritonavir	TRASCOV	OL Nigeria N = 928	December 31, 2020	Outpatients (≥ 12 years old) with COVID-19	NCT04409483 Withdrawn	NA
Ciclesonide	NA	MC, DB, PC US N = 400	January 5, 2021	Outpatient patients (≥ 12 years old) with symptomatic COVID-19	NCT04377711 Completed	Not yet published
Tissue plasminogen activator	AtTAC	MC, DB Russia N = 0	January 15, 2021	Hospitalized adult patients with severe COVID-19	NCT04453371 Withdrawn	NA
Nitazoxanide and vitamin B	NA	DB, PC US N = 1,092	February 8, 2021	Patients (12 to 120 years old) with mild-to-moderate COVID-19	NCT04486313 Completed	Not yet published

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Ruxolitinib	RUXCOVID-DEVENT	MC, DB, PC US N = 211	February 26, 2021	Patients (≥ 2 years old) with COVID-19 who require mechanical ventilation	NCT04377620 Terminated	NA
Linagliptin with or without insulin	COVID19DPP4i	DB Mexico N = 70	February 28, 2021	Hospitalized adult patients with COVID-19 and hyperglycemia	NCT04542213 Completed	Not yet published
Brensocatib	STOP-COVID 19	DB, PC UK N = 400	February 28, 2021	Hospitalized patients (≥ 16 years old) with COVID-19	NCT04817332 Completed	Not yet published
Colchicine	COLCORONA	MC, DB, PC Multi-country ^b N = 4,506	March 2021	Adult patients (≥ 40 years old) with COVID-19 and have at least one high-risk criterion	NCT04322682 HC Control No: 237317 Completed	Not yet published
Lopinavir-ritonavir	COPEP	OL Multi-country N = 326	March 24, 2021	Children and adults (≥ 16 years old) exposed to SARS-CoV-2	NCT04364022 Completed	Not yet published
Aspirin, losartan, or simvastatin, each alone or combined with another	CRASH-19	OL Multi-country N = 0	April 2021	Hospitalized adult patients (≥ 40 years old) with COVID-19	NCT04343001 Withdrawn	NA
EQ001 (Itolizumab)	EQUINOX	DB, PC Colombia N = 0	April 2021	Hospitalized adult patients with COVID-19	NCT04605926 Withdrawn	NA
Colchicine	NA	OL Spain N = 0	May 14, 2021	Hospitalized adult patients SARS-CoV-2 infection	NCT04603690 Withdrawn	NA
Favipiravir with or without azithromycin	FVR	OL Indonesia N = 210	June 30, 2021	Adult patients with COVID-19	NCT04613271 Suspended	NA

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Phase II/III						
Methylprednisolone	NA	MC, OL China N = 80	April 13, 2020	Hospitalized adult patients with COVID-19	NCT04244591 Completed	Not yet published
RPH-104 or olokizumab	NA	Adaptive, MC, DB, PC Russia Federation N = 372	July 10, 2020	Adult patients with severe SARS-CoV-2 infection	NCT04380519 Completed	Not yet published
Ivermectin	NA	OL Egypt N = 304	July 14, 2020	Asymptomatic family contact (≥ 6 years old) with patients with confirmed COVID-19	NCT04422561 Completed	Results posted on ClinicalTrials.gov
Sarilumab	NA	DB, PC US N = 1,912	July 24, 2020	Hospitalized adult patients with SARS-CoV-2	NCT04315298 HC Control No: 237332 Completed	Not yet published
Sulodexide	SuIES-COVID	OL, PC Mexico N = 243	September 7, 2020	Adult patients (40 to 80 years old) with COVID-19 symptoms	NCT04483830 Completed	Not yet published
Dutasteride, azithromycin and nitazoxanide	EST-DUTA AndroCoV	DB, PC Brazil N = 138	September 15, 2020	Adult patients with COVID-19	NCT04729491 Completed	Not yet published
DAS181	STOP COVID-19	MC, DB, PC Italy N = 0	September 30, 2020	Adult patients with SARS-CoV-2 infection with lower respiratory tract infection who require supplemental oxygen	NCT04354389 Withdrawn	NA
Metenkefalin-tridecactide	NA	OL Bosnia and Herzegovina N = 120	October 7, 2020	Hospitalized adult patients with moderate-to-severe COVID-19	NCT04374032 Completed	Not yet published

Treatment groups	Trial name	Study design, country, sample size	Trial end date ^a	Population	ClinicalTrials.gov reference and status	Publication
Ivermectin	EPIC	DB, PC Columbia N = 476	December 21, 2020	Adult patients with mild SARS-CoV-2 infection within 7 days of symptoms	NCT04405843 Completed	Not yet published
Aviptadil	COVID-AIV	MC, DB, PC US N = 196	February 22, 2021	Adult patients with COVID-19	NCT04311697 Completed	Not yet published
Colchicine	COLHEART-19	OL US N = 75	March 12, 2021	Hospitalized adult patients with COVID-19	NCT04510038 Suspended	NA
Ruxolitinib	RUXO-COVID	DB, PC Brazil N = 5	March 29, 2021	Hospitalized adult patients with COVID-19 pneumonia	NCT04477993 Terminated	NA

ACEi= angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blockers; ARDS = acute respiratory distress syndrome; MC = multi-centre; NA = not applicable, OL = open label; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

^a Actual trial completion, withdrawal, termination, or suspension date as indicated in ClinicalTrials.gov.

^b Includes Canada.